BlossomHill Therapeutics aligns with FDA on 50 mg twice daily as recommended Phase 2 dose for BH-30643

BlossomHill Therapeutics announced alignment with the FDA on 50 mg twice daily as the recommended Phase 2 dose for its drug candidate BH-30643.

Detected & updated continuously · Source: Nebula